Their radiolabeled derivatives, 64Cu-bevacizumab, which binds VEGF-A, or 89Zr-ramucirumab, which specifically targets VEGFR-2, have been used for cancer detection by targeting the VEGF family [12,13,14]. This evidence concerns the gene KDR and cancer.